

- effects in nonremission patients undergoing allogeneic hematopoietic cell transplantation with a conventional cytoreductive or reduced-intensity regimen. *Biol. Blood Marrow Transplant* 2007; 13: 932-941, 2007.
68. Onishi Y, Mori S, Kusumoto S, Sugimoto K, Akahane D, Morita-Hoshi Y, Kim SW, Fukuda T, Heike Y, Tanosaki R, Tobinai K, and Takaue Y. Unrelated-donor bone marrow transplantation with a conditioning regimen including fludarabine, busulfan, and 4 Gy total body irradiation. *Int. J. Hematol.* 2007; 85: 256-263.
69. Iizuka A, Ikarashi Y, Yoshida M, Heike Y, Takeda K, Quinn G, Wakasugi H, Kitagawa M, and Takaue Y. Interleukin (IL)-4 promotes T helper type 2-biased natural killer T (NKT) cell expansion, which is regulated by NKT cell-derived interferon-gamma and IL-4. *Immunology* 2007; 123: 100-107.
70. Ikeda Y, Kojima T, Kuroda S, Endo Y, Sakai R, Hioki M, Kishimoto H, Uno F, Kagawa S, Watanabe Y, Hashimoto Y, Urata Y, Tanaka N, Fujiwara T. A novel antiangiogenic effect for telomerase-specific virotherapy through host immune system. *J. Immunol.*, 2009; 182: 1763-1769.
71. Kurihara Y., Watanabe Y, Onimatsu H, Kojima T, Shirota T, Hatori M, Liu D, Kyo S, Mizuguchi H, Urata Y, Shintani S, Fujiwara T. Telomerase-specific virotheranostics for human head and neck cancer. *Clin. Cancer Res.*, 2009; 15: 2335-2343.
72. Nakajima O, Matsunaga A, Ichimaru D, Urata Y, Fujiwara T, Kawakami K. Telomerase-specific virotherapy in an animal model of human head and neck cancer. *Mol. Cancer Ther.*, 2009; 8: 171-177.
73. Ouchi M., Kawamura H, Urata Y, Fujiwara T. Antiviral activity of cidofovir against telomerase-specific replication-selective oncolytic adenovirus, OBP-301 (Telomelysin). *Invest. New Drugs*, 2009; 27: 241-245.
74. Liu D, Kojima T, Ouchi M, Kuroda S, Watanabe Y, Hashimoto Y, Onimatsu H, Urata Y, Fujiwara T. Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer. *Mol. Cancer Ther.*, 2009; 8: 980-987.
75. Maida Y, Kyo S, Sakaguchi J, Mizumoto Y, Hashimoto M, Mori N, Ikoma T, Takakura M, Urata Y, Fujiwara T, Inoue M. Diagnostic potential and limitation of imaging cancer cells in cytological samples using telomerase-specific replicative adenovirus. *Int. J. Oncol.*, 2009; 34: 1549-1556.
76. Takakura M, Nakamura M, Kyo S, Hashimoto M, Mori N, Ikoma T, Mizumoto Y, Fujiwara T, Urata Y, Inoue M. Intraperitoneal administration of telomerase-specific oncolytic adenovirus sensitizes ovarian cancer cells to cisplatin and affects survival in a xenograft model with peritoneal dissemination. *Cancer Gene Ther.*, 2009; (Epub ahead of print).
77. Kishimoto H, Zhao M, Hayashi K, Urata Y, Tanaka N, Fujiwara T, Penman S, Hoffman RM. In vivo internal tumor illumination by telomerase-dependent adenoviral GFP for precise surgical navigation. *Proc. Natl. Acad. Sci. U S A*, 2009; 106: 14514-14517.
78. Kojima T, Hashimoto Y, Watanabe Y, Kagawa S, Uno F, Kuroda S, Tazawa H, Kyo S, Mizuguchi H, Urata Y, Tanaka N, Fujiwara T. A simple biological imaging system for detecting viable human circulating tumor cells. *J. Clin. Invest.*, 2009; 119: 3172-3181.
79. Nakajima O, Ichimaru D, Urata Y, Fujiwara T, Horibe T, Kohno M, Kawakami

- K. Use of telomelysin (OBP-301) in mouse xenografts of human head and neck cancer. *Oncol. Rep.*, 2009; 22: 1039-1043.
80. Kishimoto H, Urata Y, Tanaka N, Fujiwara T, Hoffman RM. Selective metastatic tumor labeling with GFP and killing by systemic administration of telomerase-dependent adenoviruses. *Mol. Cancer Ther.*, 2009; 8: 3001-3008.
81. Nemunaitis J, Tong AW, Nemunaitis M, Senzer N, Phadke AP, Bedell C, Adams N, Zhang YA, Maple PB, Chen S, Pappen B, Burke J, Ichimaru D, Urata Y, Fujiwara T. A phase I study of telomerase specific replication competent oncolytic adenovirus (Telomelysin) for various solid tumors. *Mol. Ther.*, 2009; (Epub ahead of print).
82. Fujiwara T. Telomerase-specific virotherapy for human squamous cell carcinoma. *Expert Opin. Biol. Th.*, 2009; 9: 321-329.
83. Fujiwara T, Urata Y, Tanaka N. Telomerase-specific gene and vector-based therapies for human cancer. In "Telomeres and Telomerase in Cancer" (Hiyama, K., ed.), pp293-312, Humana Press, New York, USA, 2009.
84. Kyo S, Takakura M, Fujiwara T, Inoue M. Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers. *Cancer Sci* 2008; 99: 1528-1538.
85. Endo Y, Sakai R, Ouchi M, Onimatsu H, Hioki M, Kagawa S, Uno F, Watanabe Y, Urata Y, Tanaka N, Fujiwara T. Virus-mediated oncolysis induces danger signal and stimulates cytotoxic-T-lymphocyte activity via proteasome activator upregulation. *Oncogene* 2008; 27: 2375-2381.
86. Hashimoto Y, Watanabe Y, Shirakiya Y, Uno F, Kagawa S, Kawamura H, Nagai K, Tanaka N, Kumon H, Urata Y, Fujiwara, T. Establishment of Biological and Pharmacokinetic Assays of Telomerase-Specific Replication-Selective Adenovirus (TRAD). *Cancer Sci* 2008; 99:385-390.
87. Hioki M, Kagawa S, Fujiwara T, Ikeda Y, Kojima T, Sakai R, Uno F, Teraishi F, Shirakiya Y, Watanabe Y, Hashimoto Y, Urata Y, Tanaka N, Fujiwara T. Combination of oncolytic adenovirotherapy and Bax gene therapy in human cancer xenografted models. Potential merits and hurdles for combination therapy. *Int J Cancer* 2008; 122: 2628-2633.
88. Yokoyama T, Iwado E, Kondo Y, Aoki H, Hayashi Y, Georgescu MM, Sawaya R, Hess KR, Mills GB, Kawamura H, Hashimoto Y, Urata Y, Fujiwara T, Kondo S. Autophagy-inducing agents augment the antitumor effect of telomerase-selved oncolytic adenovirus OBP-405 on glioblastoma cells. *Gene Ther* 2008; 15: 1233-1239.
89. Horie K, Tsuchihara M, Nakatsura T. Silencing of SPARC inhibits the growth of human melanoma cells with G1 arrest induction. *Cancer Sci.* 2009, in press.
90. Yokomine K, Senju S, Nakatsura T, Irie A, Hayashida Y, Ikuta Y, Harao M, Imai K, Baba H, Iwase H, Nomori H, Takahashi K, Daigo Y, Tsunoda T, Nakamura Y, Sasaki Y, Nishimura Y. The forkhead box M1 transcription factor as a candidate of target for anti-cancer immunotherapy. *Int J Cancer.* 2009, in press.
91. Shirakawa H, Suzuki H, Shimomura M, Kojima M, Gotohda N, Takahashi S, Nakagohri T, Konishi M, Kobayashi N, Kinoshita T, Nakatsura T. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. *Cancer Sci.* 2009; 100(8):1403-1407.
92. Hayashi E, Motomura Y, Shirakawa H, Yoshikawa T, Oba N, Nishinakagawa S, Mizuguchi Y, Kojima T, Nomura K, Nakatsura T. Detection of glypican-3-specific CTLs in chronic

- hepatitis and liver cirrhosis. *Oncol Rep.* 2009; 22:149-154.
93. Shirakawa H, Kuronuma T, Nishimura Y, Hasebe T, Nakano M, Gotohda N, Takahashi S, Nakagohri T, Konishi M, Kobayashi N, Kinoshita T, Nakatsura T. Glypican-3 is a useful diagnostic marker for component of Hepatocellular Carcinoma in Human Liver Cancer. *Int J Oncol.* 2009; 34:649-656.
 94. Ikuta Y*, Hayashida Y*, Hirata S, Irie A, Senju S, Kubo T, Nakatsura T, Monji M, Sasaki Y, Baba H, Nishimura Y. (*These two authors contributed equally.) Identification of the H2-K^d-restricted CTL epitopes of a tumor-associated antigen, SPARC, which can stimulate antitumor immunity without causing autoimmune disease in mice. *Cancer Sci.* 2009; 100(1):132-137.
 95. Harao M, Hirata S, Irie A, Senju S, Nakatsura T, Komori H, Ikuta Y, Yokomine K, Imai K, Inoue M, Harada K, Mori T, Tsunoda T, Nakatsuru S, Daigo Y, Nomori H, Nakamura Y, Baba H, Nishimura Y. HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL. *Int J Cancer.* 2008; 123(11):2616-2625.
 96. Muchemwa F. C, Nakatsura T, Fukushima S, Nishimura Y, Kageshita T, Ihn H. Differential Expression of Heat Shock Protein 105 in Melanoma and Melanocytic Naevi. *Melanoma Res.* 2008; 18(3):166-171.
 97. Motomura Y, Ikuta Y, Kuronuma T, Komori H, Ito M, Tsuchihara M, Tsunoda Y, Shirakawa H, Baba H, Nishimura Y, Kinoshita T, Nakatsura T. HLA-A2 and -A24- restricted glypican-3-derived peptide vaccine induce specific CTLs: Preclinical study using mice. *Int J Oncol.* 2008; 32:985-990.
 98. Yokomine K, Nakatsura T, Senju S, Nakagata N, Minohara M, Kira JI, Motomura Y, Kubo T, Sasaki Y, Nishimura Y. Regression of intestinal adenomas by vaccination with heat shock protein 105-pulsed bone marrow-derived dendritic cells in *Apc^{Min/+}* mice. *Cancer Sci.* 2007; 98(12):1930-1935.
 99. Tanaka-Harada Y, Kawakami M, Oka Y, Tsuboi A, Katagiri T, Elisseeva O, Nishida S, Shirakata T, Hosen N, Fujiki F, Murao A, Nakajima H, Oji Y, Kanda Y, Kawase I, Sugiyama H. Biased usage of BV gene families of T cell receptors of WT1 (Wilms' tumor gene)-specific CD8⁺ T cells in patients with myeloid malignancies, *Cancer Science*, in press.
 100. Murao A, Oka Y, Tsuboi A, Elisseeva OA, Harada Y, Fujiki F, Nakajima H, Nishida S, Hosen N, Shirakata T, Hashimoto N, Myoui A, Ueda T, Takeda Y, Osaki T, Enomoto T, Yoshikawa H, Kimura T, Oji Y, Kawase I, Sugiyama H. High frequencies of less differentiated and more proliferative WT1-specific CD8⁺ T cells in bone marrow (BM) in tumor-bearing patients: an important role of BM as a secondary lymphoid organ., *Cancer Science*, in press.
 101. Tamura H, Dan K, Yokose N, Iwakiri R, Ohta M, Sakamaki H, Tohyama K, Kondo A, Hyodo H, Nakamura K, Yamashita T, Elisseeva O. A, Oka Y, Oji Y, Sugiyama H, Ogata K. Prognostic Significance of WT1 mRNA and anti-WT1 Antibody Levels in Peripheral Blood in Patients with Myelodysplastic Syndromes. *Leukemia Research*, in press.

102. Ohta H, Hashii Y, Yoneda A, Takizawa S, Kusuki S, Tokimasa S, Fukuzawa M, Tsuboi A, Murao A, Oka Y, Oji Y, Aozasa K, Nakatsuka S, Sugiyama H, Ozono K. WT1 (Wilms' tumor 1) peptide immunotherapy for childhood rhabdomyosarcoma, *Pediatric Hematology and Oncology*, 2009; 26: 74-83.
103. Ohno S, Dohi S, Ohno Y, Kyo S, Sugiyama H, Suzuki N, Inoue M. Immunohistochemical Detection of WT1 protein in endometrial cancer, *Anticancer Research* 2009; 29: 1691-5.
104. Izumoto S, Tsuboi A, Oka Y, Suzuki T, Hashiba T, Kagawa N, Hashimoto N, Maruno M, Elisseeva OA, Shirakata T, Kawakami M, Oji Y, Nishida S, Ohno S, Kawase I, Hatazawa J, Morita S, Sakamoto J, Sugiyama H, Yoshimine T. Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. *J Neurosurg*, 2008; 108: 963-971.
105. Li Z, Oka Y, Tsuboi A, Fujiki F, Harada Y, Nakajima H, Masuda T, Fukuda Y, Kawakatsu M, Morimoto S, Katagiri T, Tatsumi N, Hosen N, Shirakata T, Nishida S, Kawakami Y, Uda K, Kawase I, Oji Y, Sugiyama H. Identification of a WT1 protein-derived peptide, WT1187 as an HLA-A*0206-restricted, WT1-specific CTL epitope" is currently at the following stage of production. *Microbiol Immunol*, 2008; 52: 551-558.
106. Fujiki F, Oka Y, Kawakatsu M, Tsuboi A, Nakajima H, Elisseeva OA, Harada Y, Li Z, Tatsumi N, Kamino E, Shirakata T, Nishida S, Taniguchi Y, Kawase I, Oji Y, Sugiyama H. A WT1 protein-derived, naturally processed 16-mer peptide, WT1332, is a promiscuous helper peptide for induction of WT1-specific Th1-type CD4+ T cells. *Microbiol Immunol*, 2008; 52: 591-600.
107. Nishio T, Inaniwa T, Inoue K, Miyatake A, Nakagawa K, Yoda K, Ogino T: Experimental verification of the utility of positron emitter nuclei generated by photonuclear reactions for the X-ray beam monitoring in a phantom. *Radiat Med* 2007; 25: 516-522.
108. Nishio T., Miyatake A., Inoue K., Katsuta S., Gomi-Miyagishi T., Kohno R., Kameoka S., Nakagawa K., Ogino T. Experimental verification of proton beam monitoring in a human body by use of activity image of positron-emitting nuclei generated by nuclear fragmentation reaction. *Radiol. Phys. Technol.* 2008; 1(1): 44-54.
109. Nishio T., Miyatake A., Ogino T., Nakagawa K., Saijo N., Esumi H. The development and clinical use of a beam ON-LINE PET system mounted on a rotating gantry port in proton therapy. *Int. J. Radiat. Oncol. Biol. Phys.* 2009 in press.
110. Miyatake A., Nishio T., Ogino T., Saijo N., Esumi H., Uesaka M. Measurement and verification of positron emitter nuclei generated at each treatment site by target nuclear fragment reactions in proton therapy. *Med. Phys.* 2009 in submission.

111. Hong JS, Muragaki Y, Nakamura R, Hashizume M, Iseki H, A neurosurgical navigation system based on intraoperative tumour remnant estimation, *Journal of Robotic Surgery*, 2007; 1(1):91-97.
112. Ozawa N, Muragaki Y, Nakamura R, Iseki H, Intraoperative diffusion-weighted imaging for visualization of the pyramidal tracts, Part I:pre-clinical validation of the scanning protocol, *Minimally Invasive Neurosurgery* 2008; 51:63-66.
113. Ozawa N, Muragaki Y, Nakamura R, Iseki H, Intraoperative Diffusion-weighted imaging for vizualization of the pyramidal tracts. Part II: Clinical study of usefulness and efficacy, *Minimally Invasive Neurosurgery* 2008; 51:67-71.
114. Shinohara C, Muragaki Y, Maruyama T, Shimizu S, Tanaka M, Kubota Y, Oikawa O, Nakamura R, Iseki H, Kubo O, Takakura K, Hori T, Long-term Prognostic assessment of 185 Newly Diagnosed Gliomas-Grade III Glioma Showed Prognosis comparable to That of Grade II Glioma, *Jpn J Clin Oncol* 2008; 38(11):730-733.
115. Iseki H, Nakamura R, Muragaki Y, Suzuki T, Chernov M, Hori T, Takakura K, Advanced computer-aided Intraoperative Technologies for Information-guided Surgical Management of Gliomas: Tokyo Women's Medical University Experience. *Minim Invas Neurosurg* 2008; 51:285-291.
116. Chernov M, Muragaki Y, Ochiai T, Taira T, Ono Y, Usukura M, Maruyam T, Nakay K, Nakamura R, Iseki H, Kubo O, Hori T, Takakura K, : Spectroscopy-supported frame-based image-guided stereotactic biopsy of parenchymal brain lesions: Comparative evaluation of diagnostic yield and diagnostic accuracy. *Clinical Neurology and Neurosurgery* 111 2009; 527- 535.
117. Muragaki Y, Mikhail Chernov, Tajika Y, Kubo O, Iseki H, Hori T, Takakura K: Coincidence of central neurocytoma and multiple glioblastomas: a rare case report. *J Neurooncol* (2009) 93:431- 435.
118. Ozawa N, Muragaki Y, Nakamura R, Iseki H, Identification of the Pyramidal tract by Neuronavigation Based on Intraoperative Diffusion-Weighted Imaging Combined with Subcortical Stimylation. *Stereotact Funct Neurosurg* (2009) 87:18-24.
119. Ozawa N, Muragaki Y, Nakamura R, Hori T, Iseki H, Shift of the Pyramidal Tract During Resection of the Intraaxial Brain Tumors Estimated by Intraoperative Diffusion-Weighted Imaging. *Neurol Med Chir(Tokyo)* (2009) 49 ;51-56.
120. Ikuta S, Muragaki Y, Maruyama T, Ogata T, Iseki H, Assessment of Effect and Toxicity of Temozolomide Combined with Radiation Therapy for Newly-Diagnosed Glioblastoma in Japan. *J Tokyo Wom Med Univ.* (2009) 79(12):12-17.
121. Nagata Y, Hiraoka M, Mizowaki T, Narita Y, Matsuo Y, Norihisa Y, Onishi H, Shirato H. Survey of stereotactic body

- radiation therapy in Japan by the Japan 3-D Conformal External Beam Radiotherapy Group. *Int J Radiat Oncol Biol Phys* 2009; 75: 343-347.
122. Inoue T, Shimizu S, Onimaru R, Takeda A, Onishi H, Nagata Y, Kimura T, Karasawa K, Arimoto T, Hareyama M, Kikuchi E, Shirato H. Clinical Outcomes of Stereotactic Body Radiotherapy for Small Lung Lesions Clinically Diagnosed as Primary Lung Cancer on Radiologic Examination. *Int J Radiat Oncol Biol Phys* 2009; 75: 683-687.
123. Nakamura M, Narita Y, Matsuo Y, Narabayashi M, Nakata M, Sawada A, Mizowaki T, Nagata Y, Hiraoka M. Effect of audio coaching on correlation of abdominal displacement with lung tumor motion. *Int J Radiat Oncol Biol Phys* 2009; 75: 558-563.
124. Kaneyasu Y, Nagai N, Nagata Y, Hashimoto Y, Yuki S, Murakami Y, Kenjo M, Kakizawa H, Toyota N, Fujiwara H, Kudo Y, Ito K. Intra-arterial infusion chemotherapy using cisplatin with radiotherapy for Stage III squamous cell carcinoma of the cervix. *Int J Radiat Oncol Biol Phys* 2009; 75: 369-377.
125. Kenjo M, Uno T, Murakami Y, Nagata Y, Oguchi M, Saito S, Numasaki H, Teshima T, Mitsumori M. Radiation therapy for esophageal cancer in Japan: results of the Patterns of Care Study 1999-2001. *Int J Radiat Oncol Biol Phys* 2009; 75: 357-363.
126. Sakamoto T, Oya N, Shibuya K, Nagata Y, Hiraoka M. Dose-response relationship and dose optimization in radiotherapy of postoperative keloids. *Radiotherapy and Oncology* 2009; 91: 271-276.
127. Matsuura K, Kimura T, Kashiwado K, Fujita K, Akagi Y, Yuki S, Murakami Y, Wadasaki K, Monzen Y, Ito A, Kagemoto M, Mori M, Ito K, Nagata Y. Results of a preliminary study using hypofractionated involved field radiation therapy and concurrent carboplatin/paclitaxel in the treatment of locally advanced Non-Small-Cell lung cancer. *Int J Clin Oncol* 2009; 14: 408-415.
128. Numasaki H, Teshima T, Shibuya H, Nishio M, Ikeda H, Ito H, Sekiguchi K, Kamikonya N, Koizumi M, Tago M, Nagata Y, Masaki H, Nishimura T, Yamada S. National structure of radiation oncology in Japan with special reference to designated cancer care hospitals. *Int J Clin Oncol* 2009; 14: 237-244.
129. Zhu SY, Mizowaki T, Norihisa Y, Takayama K, Nagata Y, Hiraoka M. Comparisons of the impact of systematic uncertainties in patient setup and prostate motion on doses to the target among different plans for definitive external-beam radiotherapy for prostate cancer. *Int. J. Clin. Oncol.* 2008; 13: 54-61.
130. Norihisa Y, Nagata Y, Takayama K, Matsuo Y, Sakamoto T, Samamoto M, Mizowaki T, Yano S, Hiraoka M. Stereotactic body radiotherapy for oligometastatic lung tumors. *Int. J. Radia. Oncol. Biolo. Phys* 2008; 72; 398-403.

131. Chvetsov AV, Palta JJ, Nagata Y. Time-dependent cell disintegration kinetics in lung tumors after irradiation. *Phys.Med.Biolo* 2008; 53; 2413-2423.
132. Teshima T, Numasaki H, Shibuya H, Nishio M, Ikeda H, Ito H, Sekiguchi K, Kamikonya N, Koizumi M, Tago M, Nagata Y, Masaki H, Nishimura T, Yamada S. Japanese structure survey of radiation oncology in 2005 based on institutional stratification of patterns of care study. *Int. J. Radia. Oncol. Biolo. Phys.* 2008; 72; 144-152.
133. Itami J, Sumi M, Beppu Y, Chuman H, Kawai A, Murakami N, Morota M, Mayahara H, Yoshimura R, Ito Y. High-Dose-Rate Brachytherapy Alone in Postoperative Soft Tissue Sarcomas with Close/Positive Margins. *Brachytherapy* 2009; in press
134. Sekine I, Sumi M, Ito Y, Tanai C, Nokihara H, Yamamoto N, Kunitoh H, Ohe Y, Tamura T., Gender Difference in Treatment Outcomes in Patients with Stage III Non-small Cell Lung Cancer Receiving Concurrent Chemoradio-therapy.
135. Sanuki-Fujimoto N, Sumi M, Ito Y, mai A, Kagami Y, Sekine I, Kunitoh H, Ohe Y, Tamura T, Ikeda H. Relation between elective nodal failure and irradiated volume in non-small-cell lung cancer (NSCLC) treated with radiotherapy using conventional fields and doses. *Radiotherapy and Oncology.* 2009; 91(3) : 433-437.
136. Sekine I, Sumi M, Ito Y, Kato T, Fujisaka Y, Nokihara H, Yamamoto N, Kunitoh H, Ohe Y, Tamura T. Phase I Study of Cisplatin Analogue Nedaplatin, Paclitaxel, and Thoracic Radiotherapy for Unresectable Stage III Non-Small Cell Lung Cancer. *Jpn J Clin Oncol.* 2007; 37: 175-180.
137. Uno T, Sumi M, Kihara A, Numasaki H, Kawakami H, Ikeda H, Mitsumori M, Teshima T. Japanese PCS Working Subgroup of Lung Cancer. Postoperative radiotherapy for non-small-cell lung cancer: results of the 1999-2001 patterns of care study nationwide process survey in Japan. *Lung Cancer* 2007; 56:357-362.
138. Watanabe S, and Asamura H. Lymph node dissection for lung cancer: significance, strategy, and technique. *J Thorac Oncol.* 2009 ;4(5) :652-7.
139. Chang JW, Asamura H, Kawachi R, and Watanabe S. Gender difference in survival of resected non-small cell lung cancer: histology-related phenomenon? *J Thorac Cardiovasc Surg.* 2009 ;137(4) :807-12.
140. Kawachi R, Watanabe S, and Asamura H. Clinicopathological characteristics of screen-detected lung cancers. *J Thorac Oncol.* 2009;4(5) :615-9. Erratum in: *J Thorac Oncol.* 2009;4(8) :1045.
141. Watanabe S, Suzuki K, and Asamura H. Superior and basal segment lung cancers in the lower lobe have different lymph node metastatic pathways and prognosis. *Ann Thorac Surg* 2008;85:1026-31.

142. Ishizumi T, Tateishi U, Watanabe S, and Matsuno Y. Mucoepidermoid carcinoma of the lung: High-resolution CT and histopathologic findings in five cases. *Lung Cancer* 2008; 60:125-131.
143. Kawaguchi T, Watanabe S, Kawachi R, Suzuki K, and Asamura H. The Impact of Residual Tumor Morphology on Prognosis, Recurrence, and Fistula Formation after Lung Cancer Resection. *Journal of Thoracic Oncology* 2008; 3:599-603.
144. Kawachi R, Watanabe S, Suzuki K, and Asamura H. Clinical application of costal coaptation pins made of hydroxyapatite and poly-L-lactide composite for posterolateral thoracotomy. *European Journal of Cardio-thoracic Surgery* 2008; 34:510-513.
145. Ishizumi T, Tateishi U, Watanabe S, Maeda T, and Arai Y. F-18 FDG PET/CT imaging of low-grade mucoepidermoid carcinoma of the bronchus. *Ann Nucl Med* 2007;21:299-302.
146. Fukui T, Tsuta T, Furuta K, Watanabe S, Asamura H, Ohe Y, Maeshima AM, Shibata T, Masuda N, and Matsuno Y. Epidermal growth factor receptor mutation status and clinicopathological features of combined small cell carcinoma with adenocarcinoma of the lung. *Cancer Sci* 2007; 98:1714-1719.
147. Kato Y, Tsuta K, Seki K, Maeshima AM, Watanabe S, Suzuki K, Asamura H, Tsuchiya R, and Matsuno Y. Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. *Mod Pathol* 2007;20:215-20.
148. Nishiyama N, Yamamoto S, Matsuoka N, Fujimoto H, and Moriya Y. Simultaneous laparoscopic descending colectomy and nephroureterectomy for descending colon carcinoma and left ureteral carcinoma: report of a case. *Surg. Today* 2009; 39: 728-732.
149. Uemura H, Shinohara N, Yuasa T, Tomita Y, Fujimoto H, Niwakawa M, Mugiya S, Miki T, Nonomura N, Takahashi M, Hasegawa Y, Agata N, Houk B, Naito S, and Akaza H. A Phase II Study of Sunitinib in Japanese Patients with Metastatic Renal Cell Carcinoma: Insights into the Treatment, Efficacy and Safety. *Jpn. J. Clin. Oncol* 2009; 7.
150. Nakagawa T, Kanai Y, Komiyama M, Fujimoto H, and Kakizoe T. Characteristics of prostate cancers found in specimens removed by radical cystoprostatectomy for bladder cancer and their relationship with serum prostate-specific antigen level. *Cancer Sci* 2009; 100: 1880- 1884.
151. Hinotsu S, Akaza H, Miki T, Fujimoto H, Shinohara N, Kikuchi E, Mizutani Y, Koga H, Okajima E, and Okuyama A, Japanese Urological Association. Bladder cancer develops 6 years earlier in current smokers: analysis of bladder cancer registry data collected by the cancer registration committee of the Japanese Urological Association. *Int. J. Urol* 2009; 16: 64-69.

152. Kikuchi E, Fujimoto H, Mizutani Y, Okajima E, Koga H, Hinotsu S, Shinohara N, Oya M, Miki T, and the Cancer Registration Committee of the Japanese Urological Association. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association. *Int. J. Urol* 2009; 16: 279-286.
153. Kakehi Y, Kamoto T, Shiraishi T, Ogawa O, Suzukamo Y, Fukuhara S, Saito Y, Tobisu K, Kakizoe T, Shibata T, Fukuda H, Akakura K, Suzuki H, Shinohara N, Egawa S, Irie A, Sato T, Maeda O, Meguro N, Sumiyoshi Y, Suzuki T, Shimizu N, Arai Y, Terai A, Kato T, Habuchi T, Fujimoto H, and Niwakawa M. Prospective Evaluation of Selection Criteria for Active Surveillance in Japanese Patients with Stage T1cN0M0 Prostate Cancer. *Jpn J Clin Oncol* 2008; 38:122-128.
154. Negishi T, and Fujimoto H. A case of locally advanced prostate cancer in the transition zone. *Jpn. J. Clin. Oncol* 2008; 38: 164.
155. Shintaku I, Satoh M, Okajima E, Fujimoto H, Kamoto T, Ogawa O, Kawai K, Akaza H, Tsukamoto T, Naito S, Miki T, and Arai Y. Survival of metastatic germ cell cancer patients assessed by international germ cell consensus classification in Japan. *Jpn. J. Clin. Oncol* 2008; 38: 281-287.
156. Kamidono S, Ohshima S, Hirao Y, Suzuki K, Arai Y, Fujimoto H, Egawa S, Akaza H, Hara I, Hinotsu S, Kakehi Y, and Hasegawa T, Working Group for Creation of Clinical Practice Guidelines for Prostate Cancer, The Japanese Urological Association. Evidence-based clinical practice Guidelines for Prostate Cancer (Summary - JUA 2006 Edition). *Int. J. Urol* 2008; 15: 1-18.
157. Miyake M, Sugano K, Kawashima K, Ichikawa H, Hirabayashi K, Kodama T, Fujimoto H, Kakizoe T, Kanai Y, Fujimoto K, Hirao Y. Sensitive detection of FGFR3 mutations in bladder cancer and urine sediments by peptide nucleic acid-mediated real-time PCR clamping. *Biochem. Biophys. Res. Commun* 2007; 362: 865- 871.
158. Kouno T, Ando M, Yonemori K, Matsumoto K, Shimizu C, Katsumata N, Komiyama M, Okajima E, Matsuoka N, Fujimoto H, Fujiwara Y. Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen. *Eur. Urol* 2007; 52: 1115-1122.
159. Sakuraba M, Asano T, Yano T, Yamamoto S, and Moriya Y. Reconstruction of an enterocutaneous fistula using a superior gluteal artery perforator flap. (Case report) *JPRAS* 62: 108-111, 2009
160. Kusters M, C.J.H. van de Velde, R.G.H. Beet-Tan, Akasu T, Fujita S, Yamamoto S, and Moriya Y. Patterns of local recurrence in rectal cancer: A

- single-center experience. *Ann Surg Oncol* 16:289-296, 2009
161. Ishiguro. S, Yamamoto. S, Fujita. S, Akasu. T, Kusters. M, and Moriya. Y. Pelvic exenteration for clinical T4 rectal cancer: oncologic outcome in 93 patients at a single institution over a 30-year period. *Surgery* 145(2): 189-195, 2009
162. Kusters. M, Beets GL, Van de Velde CJH, Beets-Tan RG, Marijnen. CA, Rutten. HJ, Putter. H, and Moriya. Y. A comparison between the treatment of low rectal cancer in Japan and the Netherlands, with focus on the patterns of local recurrence. *Annals of Surgery* 249(2):229-235, 2009
163. Fujita. S, Yamamoto. S, Akasu. T, and Moriya. Y. Risk factors of lateral pelvic lymph node metastasis in advanced rectal cancer. *Int J Colorectal Dis* 24: 1085-1090, 2009
164. Akasu. T, Sugihara. K, and Moriya. Y. : Male urinary and sexual function after mesorectal excision alone or in combination with extended lateral pelvic lymph node dissection for rectal cancer. *Ann Surg Oncol* 10: 2779-2786, 2009
165. Moriya. Y. : Differences in rectal cancer surgery east versus west. *Lancet Oncol* 10: 1026-1027, 2009
166. Kusters M, Sc Geerard L Beets, C. J. H. van de Velde, Regina Beets-Tan, Marijnen C, Harm Rutten H, Putter H, Moriya Y. : A comparison between the treatment of low rectal cancer in Japan and the Netherlands, with focus on the patterns of local recurrence. *Annals of Surgery* Oct 8 2008 in press.
167. Akasu T, Yamaguchi T, Fujimoto Y, Ishiguro S, Yamamoto S, Fujita S and Moriya Y. Abdominal sacral resection for posterior pelvic recurrence of recatal carcinoma: analyses of prognostic factors and recurrence patterns. *Ann Surg Oncol* 14(1):74-83, 2007.
168. Uehara K, Shimoda T, Nakanishi Y, Taniguchi H, Akasu T, Fujita S, Yamamoto S and Moriya Y. Clinicopathological significance of fibrous tissue around the fixed recurrent rectal cancer in the pelvis. *Br J Surg* 94:1530-1535, 2007.
169. Uehara K, Nakanishi Y, Shimoda T, Taniguchi H, Akasu T and Moriya Y. Clinicopathological significance of microscopic abscess formation at the invasive margin of advanced low rectal cancer. *Br J Surg* 94: 239-243, 2007.
170. Uehara M, Yamamoto S, Fujita S, Akasu T, Moriya Y and Morisue A. Isolated right external iliac lymph node recurrence from a primary cecum carcinoma: Report of a case. *Jpn J Clin Oncol* 37(3): 230-232, 2007.
171. Nakajima T, Saito Y, Matsuda T, Hoshino T, Yamamoto S and Moriya Y, Saito D. Minute depressed-type submucosal invasive cancer; 5mm in diameter with intermediate lymph-node metastasis. Report of a Case. *Dis Colon Rectum* 677-681, 2007.

172. Uehara K, Yamamoto S, Fujita S, Akasu T and Moriya Y. Impact of Upward Lymph Node Dissection on Survival Rates in Advanced Lower Rectal Carcinoma. *Dig Surg* 24(5):375-381, 2007.
173. Ishibashi Y, Yamamoto S, Yamada Y, Fujita S, Akasu T and Moriya Y. Laparoscopic resection for malignant lymphoma of the ileum causing ileocecal intussusception -Case Report-. *Surg Laparosc Endosc Percutan Tech* 17(5): 444-446, 2007.
174. Fujita S, Saito N, Yamada T, Takii Y, Kondo K, Ohue M, Ikeda E and Moriya Y. Randomized, Multicenter Trial of Antibiotic Prophylaxis in Elective Colorectal Surgery. *Archives of Surgery*, 142: 657-661, 2007
175. Fujita S, Yamamoto S, Akasu T, Moriya Y, Taniguchi H and Shimoda T. Quantification of CD10 mRNA in colorectal cancer and relationship between mRNA expression and liver metastasis, *Anticancer Research* 27: 3307-3312, 2007.
176. Terauchi T, Tateishi U, Maeda T, Kanou D, Daisaki H, Moriya Y, Moriyama N and Kakizoe T. A case of colon cancer detected by carbon-11 choline positron emission tomography/ computed tomography: An initial report. *Jpn J Clin Oncol* 37(10): 797-800, 2007.
177. Yamamoto S, Fujita S, Akasu T, Ishiguro S, Kobayashi Y and Moriya Y. Wound infection after elective laparoscopic surgery for colorectal carcinoma. *Surg Endosc* 21: 2248-2252, 2007.
178. Fujita S, Nakanishi Y, Taniguchi H, Yamamoto S, Akasu T, Moriya Y and Shimoda T. Cancer invasion to auerbach's plexus is an important prognostic factor in patients with pT3-pT4 colorectal cancer. *Dis Colon Rectum* 50: 1860-1866, 2007.
179. Nakagohri T, Kinoshita T, Konishi M, Takahashi S, Gotohda N, Kobayashi S, Kojima M, Miyauchi H, and Asano T. Inferior head resection of the pancreas for intraductal papillary mucinous neoplasms. *J. Hepatobiliary. Pancreat. Surg.* 2009; [Epub ahead of print].
180. Fujita T, Nakagohri T, Gotohda N, Takahashi S, Konishi M, Kojima M, and Kinoshita T. Evaluation of the Prognostic Factors and Significance of Lymph Node Status in Invasive Ductal Carcinoma of the Body or Tail of the Pancreas. *Pancreas* 2009; [Epub ahead of print].
181. Fujita T, Kojima M, Gotohda N, Takahashi S, Nakagohri T, Konishi M, Ochiai A, and Kinoshita T. Incidence, clinical presentation and pathological features of benign sclerosing cholangitis of unknown origin masquerading as biliary carcinoma. *J. Hepatobiliary. Pancreat. Surg.* 2009; [Epub ahead of print]
182. Shirakawa H, Suzuki H, Shimomura M, Kojima M, Gotohda N, Takahashi S, Nakagohri T, Konishi M, Kobayashi N, Kinoshita T, and Nakatsura T. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. *Cancer Sci* 2009; 100:

- 1403-1407.
183. Shirakawa H, Kuronuma T, Nishimura Y, Hasebe T, Nakano M, Gotohda N, Takahashi S, Nakagohri T, Konishi M, Kobayashi N, Kinoshita T, and Nakatsura T. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer. *Int. J. Oncol.* 2009; 34: 649-656.
184. Kobayashi S, Gotohda N, Nakagohri T, Takahashi S, Konishi M, and Kinoshita T. Risk factors of surgical site infection after hepatectomy for liver cancers. *World J. Surg.* 2009; 33: 312-317.
185. Kinoshita T, Sasako M, Sano T, Katai H, Furukawa H, Tsuburaya A, Miyashiro I, Kaji M, and Ninomiya M. Phase II trial of S-1 for neoadjuvant chemotherapy against scirrhus gastric cancer (JCOG 0002). *Gastric Cancer* 2009; 12: 37-42.
186. Hirayama A, Kami K, Sugimoto M, Sugawara M, Toki N, Onozuka H, Kinoshita T, Saito N, Ochiai A, Tomita M, Esumi H, and Soga T. Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. *Cancer Res.* 2009; 69: 4918-4925.
187. Fujita T, Gotohda N, Takahashi S, Nakagohri T, Konishi M, and Kinoshita T. Clinical and histopathological features of remnant gastric cancers, after gastrectomy for synchronous multiple gastric cancers. *J. Surg. Oncol.* 2009; 100: 466-471.
188. Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, Hiratsuka M, Tsujinaka T, Kinoshita T, Arai K, Yamamura Y and Okajima K. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. *N. Engl. J. Med.* 2008; 359: 453-462.
189. Nobuoka D, Gotohda N, Konishi M, Nakagohri T, Takahashi S and Kinoshita T. Prevention of postoperative pancreatic fistula after total gastrectomy. *World J. Surg.* 2008; 32: 2261-2266.
190. Mitsunaga S, Kinoshita T, Hasebe T, Nakagohri T, Konishi M, Takahashi S, Gotohda N and Ochiai A. Low serum level of cholinesterase at recurrence of pancreatic cancer is a poor prognostic factor and relates to systemic disorder and nerve plexus invasion. *Pancreas* 2008; 36: 241-248.
191. Kajiwar M, Kojima M, Konishi M, Nakagohri T, Takahashi S, Gotohda N, Hasebe T, Ochiai A and Kinoshita T. Autoimmune pancreatitis with multifocal lesions. *J. Hepatobiliary. Pancreat. Surg.* 2008; 15: 449-452.
192. Kajiwar M, Gotohda N, Konishi M, Nakagohri T, Takahashi S, Kojima M and Kinoshita T. Incidence of the focal type of autoimmune pancreatitis in chronic pancreatitis suspected to be pancreatic carcinoma: experience of a single tertiary cancer center. *Scand. J. Gastroenterol.* 2008; 43: 110-116.
193. Hasebe T, Konishi M, Iwasaki M,

- Nakagohri T, Takahashi S, Gotohda N, Kinoshita T and Ochiai A. Primary tumor/vessel tumor/nodal tumor classification of extrahepatic bile duct carcinoma. *Hum. Pathol.* 2008; 39: 37-48.
194. Nakagohri T, Kinoshita T, Konishi M, Takahashi S and Tanizawa Y. Clinical results of extended lymphadenectomy and intraoperative radiotherapy for pancreatic adenocarcinoma. *Hepatogastroenterology.* 2007; 54: 564-569.
195. Konishi M, Kinoshita T, Nakagohri T, Takahashi S, Gotohda N and Ryu M. Pancreas-sparing duodenectomy for duodenal neoplasms including malignancies. *Hepatogastroenterology.* 2007; 54: 753-757.
196. Nakagohri T, Kinoshita T, Konishi M, Takahashi S and Gotohda N. Surgical outcome of intraductal papillary mucinous neoplasms of the pancreas. *Ann. Surg. Oncol.* 2007; 14: 3174-3180.
197. Kobayashi A, Takahashi S, Ishii H, Konishi M, Nakagohri T, Gotohda N, Satake M, Furuse J and Kinoshita T. Factors predicting survival in advanced T-staged hepatocellular carcinoma patients treated with reduction hepatectomy followed by transcatheter arterial chemoembolization. *Eur. J. Surg. Oncol.* 2007; 33: 1019-1024.
198. Takahashi S, Nagai K, Saito N, Konishi M, Nakagohri T, Gotohda N, Nishimura M, Yoshida J and Kinoshita T. Multiple resections for hepatic and pulmonary metastases of colorectal carcinoma. *Jpn. J. Clin. Oncol.* 2007; 37: 186-192.
199. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A and Arai K. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. *N. Engl. J. Med.* 2007; 357: 1810-1820.
200. Nomura E, Sasako M, Yamamoto S, Sano T, Tsujinaka T, Kinoshita T, Furukawa H, Shimizu T, Hiratsuka M, Kobayashi O, Kurokawa Y and Tanigawa N. Risk factors for para-aortic lymph node metastasis of gastric cancer from a randomized controlled trial of JCOG9501. *Jpn. J. Clin. Oncol.* 2007; 37: 429-433.
201. Sano T. Adjuvant and neoadjuvant therapy of gastric cancer: a comparison of three pivotal studies. *Current Oncol Rep* 2008;10:191-198.
202. Sasako M, Sano T. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. *N Engl J Med* 2008;359:453-462.
203. Morita S, Sano T. Outcome of pylorus-preserving gastrectomy for early gastric cancer. *Br J Surg* 2008;95:1131-1135.
204. Oda I, Sano T. Treatment strategy after non-curative endoscopic resection of early gastric cancer. *Br J Surg* 2008;95:1495-1500.
205. Nunobe S, Sano T. Symptom evaluation of long-term postoperative outcomes after

pylorus-preserving gastrectomy for early gastric cancer. Gastric Cancer 2007;10:167-172

206. Kosaka Y, Sano T. Identification of the high-risk group for metastasis of gastric cancer cases by vascular endothelial growth factor receptor-I over-expression in peripheral blood. British J Cancer 2007;96:1723-1728.

207. Sano T. Tailoring treatments for curable gastric cancer. Br J Surg. 2007;94:263-264

208. Sasako M, Sano T. Surgical treatment of advanced gastric cancer: Japanese perspective. Dig Surg 2007; 24:101-107.

209. Tsujinaka T, Sano T. Influence of overweight on surgical complications for gastric cancer: results from a randomized control trial comparing D2 and extended para-aortic D3 lymphadenectomy (JCOG9501). Ann Surg Oncol 2007; 14:355-361.

H. 知的財産権の出願・登録状況(予定を含む。)

1. 特許取得

1) 西條 長宏

①特願 2003-102869

記察日:平成 21 年 5 月 1 日、グルクロン酸抱合酵素 1A9 による薬物解毒代謝の異常の遺伝子診断に用いることができる変異型ポリヌクレオチド及び核酸分子

2) 平家 勇司

①特願 2009-288141

遠心分離容器、遠心分離用容器の姿勢保持用アダプター及び遠心分離用用具

3) 荻野 尚

①特願 2009-064295

「荷電粒子線照射制御装置及び荷電粒子線照射方法」

②特願 2009-017114

「陽子線治療におけるポジトロン放出核種のアクティビティ分布のシミュレーション法」

③特開 2008-173299

「荷電粒子線照射装置、及び荷電粒子線照射方法」

④特開 2008-173298

「荷電粒子線照射装置」

⑤特開 2008-173297

「荷電粒子線照射装置」

⑥特願 2007-009524

「荷電粒子線照射装置」

⑦特願 2007-009541

「荷電粒子線照射装置」

⑧特願 2007-009544

「荷電粒子線照射装置、及び荷電粒子線照射方法」

4) 渡辺 俊一

①特願 2007-41498

「癌の悪性度を分類する方法、装置およびプログラム」

②特願 2006-336432

「縦隔リンパ節郭清で切除される領域を複数の区域にセグメンテーションする装置およびプログラム」

③特願 2006-336431

「肺を肺区域の単位に自動的にセグメンテーションする装置およびプログラム」

2. 実用新案登録

なし

3. その他

なし

研究成果の刊行に関する一覧表

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Kim. Y.K, Ishi i G, Goto K, Ota S, Kubota K, Murata Y, Mishima M, Saijo N, Nishiwaki Y, Ochiai. A.	Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer.	Lung Cancer	65	105-111	2009
Saito Y, Sai K, Maekawa K, Shirao K, Hamaguchi T, Yamamoto N, Kunitoh H, Ohe Y, Yamada Y, Tamura T, Yoshida T, Minami H, Ohtsu A, Matsumura Y, Saijo N and Sawada J	Close Association of UGT1A9 IVS1+399C>T with UGT1A1 *28, *6, or *60 Haplotype and its apparent influence on 7-Ethyl-10-hydroxycomptothecin (SN-38) Glucuronidation in Japanese.	Drug Meta. and Dispos	37(2)	272-276	2009
Kunitoh H, Tamura T, Shibata T, Imai M, Nishiwaki Y, Nishio M, Yokoyama A, Watanabe K, Noda K, and Saijo N., JCOG Lung Cancer Study Group, Tokyo, Japan.	A randomized trial intrapericardial bleomycin for malignant pericardial effusion with lung cancer. (JCOG9811)	B. J. Cancer	100	464-469	2009
Sekine I, Shimizu C, Nishio K, Saijo N and Tamura T.	A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with breast cancer.	Int J Clin Oncol	14(2)	112-119	2009
Matsubara J, Ono M, Negishi A, Ueno H, Okusaka T, Furuse J, Furuta K, Sugiyama E, Chiba T, Saijo N, Hirohashi S and Yamada T.	Identification of a Predictive Biomarker for Hematologic Toxicities of Gemcitabine.	J Clin. Oncol.	27(13)	2261-2268	2009

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Takeda K, Negoro S, Tamura T, Nishiwaki Y, Kurodoh S, Yokota S, Matsui K, Semba H, Nakagawa K, Takeda Y, Ando. M, Shibata T and <u>Saijo N.</u>	Phase III trial of docetaxel plus gemcitabine versus docetaxel second-line treatment for non-small cell lung cancer: results of a Japan Clinical Oncology Group trial. (JCOG0104)	Ann Oncol.	20	835-841	2009
<u>Saijo N</u> , Takeuchi M and Kunitoh H. R	Reasons for response differences seen in the V15-32, INTEREST and IPASS trials.	Nature Rev. Clin. Oncol	6(6)	287-294	2009
Kim. Y.H, Kubota K, Gotto K, Yoh K, Niho S, Ohmatsu H, <u>Saijo N</u> and Nishiwaki Y.	A Phase I study of Gemcitabine and Carboplatin in Patients with Advanced Non-Small Cell Lung Cancer and a Performance Status of 2.	Jpn J Clin Oncol	39(9)	576-581	2009
Mok. T.S, Wu Y.L, Thongprasert. S, Yang. C.H, Chiu. D.T, <u>Saijo N</u> , Sunpaweevorong P, Han B, Marnett L, Ichinose Y, Nishiwaki Y, Ohe Y, Yang J.J, Cehwaskulyong B, Jian H, Duffield. E.L, Watkins. C.L, Armour. A.A and Fukuoka M.	Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.	New Eng J Med	361(10)	947-957	2009
Kim. Y.H, Kubota K, Gotto K, Yoh K, Niho S, Ohmatsu H, <u>Saijo N</u> , Nishiwaki Y.	A phase I study of Gemcitabine and Carboplatin in patients with advanced non-small cell lung cancer and a performance status of 2.	Jpn J Clin Oncol	39(9)	576-581	2009

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Sekine I , Ichinose Y, Nishiwaki Y, Yamamoto N, Tsuboi M, Nakagawa N, Shinkai T, Negoro S, Imamura F, Eguchi K, Takeda K, Itoh Y, Tamura T, <u>Saijo N</u> and Fukuoka M.	Quality of life and disease-related symptoms in previously treated Japanese patients with non-small cell lung cancer: Result of a randomized phase III study (V-15-32) of gefitinib versus docetaxel.	Ann Oncol	20	1483-1488	2009
Matsumoto K, Arao T, Tanaka K, Kaneda H, Kudo K, Fujitani Y, Tamura D, Aomatsu K, Tamura T, Yamada Y, <u>Saijo N</u> and Nishio K.	mTOR signal and Hypoxia-Inducible Factor-1 α regulate CD133 expression in cancer cells.	Cancer Res	69(18)	7160-7164	2009
Kubota K, Niho S, Enatsu S, Nambu Y, Nishiwaki Y, <u>Saijo N</u> and Fukuoka M.	Efficacy Differences of Pemetrexed by Histology in Pretreated Patients with Stage III B/IV Non-Small Cell Lung Cancer, Review of results from an open-label randomized phase II study.	J Thorac Oncol	4(12)	1530-1536	2009
Yamamoto N, Tamura T, Kururata T, Yamamoto N, Sekine I, Kunito H, Ohe Y <u>Saijo N</u> .	A dose-finding and pharmacokinetic study of nedaplatin in elderly patients with advanced non-small cell lung cancer.	Cancer Chemotherapy and Pharmacology	65	79-88	2009
Sangha R, Lara. P.N, Adjani. A.A, Baas. P, Choy. H, Gasper. L.E, Goss. G, <u>Saijo N</u> , Schiller. J.H, Vokes. E-E, Gandara. D.R.	Cooperative Group Research Endeavors in Small-Cell Lung Cancer: Current and Future Directions.	Clin Lung Cancer	110(5)	322-330	2009

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Gandara. D, Kawaguchi. T, Crowley. J, Moon. J, Furu se. K, Kawahara. M, Teramukai. S, Ohe. Y, Kubota. K, Williamson. S. K, Gautschi. O, Lenz. H. J, McLeod. H. L, Lara. P. N, Jr. Coltman. C. A, Fukuoka. M, <u>Saijo. N</u> , Fukushima. M, Mack. P-C.	Japanese-US Common-Arm Analysis of Paclitaxel Non-Small-Cell Lung Cancer: A Model for Assessing Population-related Pharmacogenomics.	J Clin Oncol	27(21)	3540-3546	2009
Walelee. H, Loo. B. W, Jr. Kernsistine. K. H, Putnam. J. B, Jr. Edelman. M. E, Vokes. E. E, Schiller. J. H, Baas. P, <u>Saijo N</u> , Adjei. A, Goss. G, Choy. H and Gandara. D. R.	Cooperative Group Research Efforts in Thoracic Malignancies 2009: A Review from the 10 th Annual International Lung Cancer Congress.	Clin. Lung Cancer	10(6)	398-404	2009
Fujii T, Kunikane H, Okamoto H, Watanabe K, Kunitoh H, Mori K, Yokoyama A, Fukuda H, Tamura T and <u>Saijo N</u> .	A phase II study of cisplatin and irinotecan as induction chemotherapy followed by accelerated hyperfractionated thoracic radiotherapy with daily low-dose carboplatin in unresectable stage III non-small cell lung cancer: JCOG 9510.	Jpn Clin Oncol (JJCO)	39(12)	784-790	2009
Kunitoh H, Tamura T, Shibata T, Nakagawa K, Takeda K, Nishiwaki Y, Osaka Y, Noda K, Yokoyama A, <u>Saijo N</u> and JCOG Lung Cancer Study Group.	A phase II trial of dose-dense chemotherapy in patients with disseminated thymoma: report of a Japan Clinical Oncology Group trial. (JCOG9605)	British J. Cancer	101(9)	1549-1554	2009

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Tatewaki N, Maekawa K, Katori N, Kurose K, Kaniwa N, Yamamoto N, Kunitoh H, Ohe Y, Nokihara H, Sekine I, Tamura T, Yoshida T, <u>Saijo N</u> , Saito Y, Sawada J.	Genetic variations and haplotype structures of the glutathione S-transferase genes, GSTT1 and GSTM1, in a Japanese patient population.	Drug Metab. Pharmacokinet.	24(1)	118-126	2009
Tsuboi M, Ezaki K, Tobinai K, Ohashi Y, <u>Saijo N</u> .	Weekly administration of epoetin beta for chemotherapy-induced anemia in cancer patients: results of a multicenter, Phase III, randomized, double-blind, placebo-controlled study.	Jpn. J. Clin. Oncol.	39(3)	163-168	2009
Kubota K, Nishiwaki Y, Tamura T, Nakagawa K, Matsui K, Watanabe K, Hida T, Kawahara M, Katakami N, Takeda K, Yokoyama A, Noda K, Fukuoka M, <u>Saijo N</u> .	Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer.	J. Thorac. Oncol.	3(12)	1439-1445	2008
Yoh K, Nishiwaki Y, Ishii G, Goto K, Kubota K, Ohmatsu H, Niho S, Nagai K, <u>Saijo N</u> .	Mutational status of EGF R and KIT in thymoma and thymic carcinoma.	Lung Cancer	62(3)	316-320	2008
Sekine I, Yamamoto N, Nishio K, <u>Saijo N</u> .	Emerging ethnic differences in lung cancer therapy.	Br J Cancer	99(11)	1757-62	2008
Wakelee H, Kernstine K, Vokes E, Schiller J, Bass P, <u>Saijo N</u> , Adjei A, Gross G, Gaspar L, Gandara DR, Choy H, Putnam JB.	Cooperative group research efforts in lung cancer 2008: focus on advanced-stage non-small-cell lung cancer.	Clin. Lung Cancer	9(6)	346-351	2008
Kim SR, Saito Y, Maekawa K, Sugiyama E, Kaniwa N, Ueno H, Okusaka T, Ikeda M, Morizane C, Yamamoto N, Yoshida T, Kamatani N, Furuse J, Ishii H, <u>Saijo N</u> , Ozawa S, Sawada J.	Twenty novel genetic variations and haplotype structures of the DCK gene encoding human deoxycytidine kinase (dCK).	Drug Metab. Pharmacokinet.	23(5)	379-384	2008

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Kim YH, Goto K, Yoh K, Niiho S, Ohmatsu H, Kubota K, <u>Saijo N</u> , Nishiwaki Y	Performance status and sensitivity to first-line chemotherapy are significant prognostic factors in patients with recurrent small cell lung cancer receiving second-line chemotherapy.	Cancer	113(9)	2518-23	2008
<u>Saijo N</u> .	Advances in the treatment of non-small cell lung cancer.	Cancer Treat. Rev.	34(6)	521-526	2008
Maruyama R, Nishiwaki Y, Tamura T, Yamamoto N, Tsuboi M, Nakagawa K, Shinikai T, Negoro S, Imamura F, Eguchi K, Takeda K, Inoue A, Tomii K, Harada M, Masuda N, Jiang H, Itoh Y, Ichinose Y, <u>Saijo N</u> , Fukuoka M.	Phase III study V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer.	J. Clin. Oncol.	26(26)	4244-4252	2008
Kunitoh H, Kato H, Tsuboi M, Asamura H, Tada H, Nagai K, Mitsudomi T, Koike T, Nakagawa K, Ichinose Y, Okada M, Shibata T, <u>Saijo N</u> ; JCOG Lung Cancer Surgical Study Group.	A randomised phase II trial of preoperative chemotherapy of cisplatin-docetaxel or docetaxel alone for clinical stage IB/II non-small-cell lung cancer: results of a Japanese Clinical Oncology Group trial (JCOG 0204).	Br. J. Cancer	99(6)	852-857	2008
Kawai O, Ishii G, Kubota K, Murata Y, Naito Y, Mizuno T, Aokage K, <u>Saijo N</u> , Nishiwaki Y, Gemma A, Kudoh S, Ochiai A.	Predominant infiltration of macrophages and CD8 ⁺ T Cells in cancer nests is a significant predictor of survival in stage IV non small cell lung cancer.	Cancer	113(6)	1387-1395	2008
Sai K, Saito Y, Fukushima-Uesaka H, Kurose K, Kaniwa N, Kamatani N, Shiraoka K, Yamamoto N, Hamaguchi T, Kunitoh H, Ohe Y, Tamura T, Yamada Y, Minami H, Ohtsu A, Yoshida T, <u>Saijo N</u> , Sawada J.	Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients.	Cancer Chemother. Pharmacol.	62(3)	529-537	2008